Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Elena Vaghi"'
Autor:
Italia Bongarzone, Roberto Agresti, Rosaria Orlandi, Chiara Maura Ciniselli, Dario Caccia, Daniele Morelli, Vito Michele Garrisi, Chiara Bonini, Maria Grazia Daidone, Paolo Verderio, M. De Bortoli, C. Camaschella, Elena Vaghi, Silvia Veneroni, Sara Pizzamiglio
Publikováno v:
Annals of Oncology. 25:352-357
Background Currently used CA15–3 and CEA have found their clinical application particularly in the follow-up of patients with advanced disease. Novel biomarkers are urgent, especially for improving early diagnosis as well as for discriminating betw
Autor:
Elena Vaghi, Debora Formisano, Alberto Cavazza, Francesca Miccichè, Massimiliano Paci, Italia Bongarzone, Alessia Ciarrocchi, Laura Canovi, Maida De Bortoli, Sally Maramotti, Giorgio Sgarbi
Publikováno v:
Lung Cancer. 76:332-338
Epidermal growth factor receptor (EGFR) is implicated in tumor development and is highly expressed in many human tumors. EGFR overexpression has been observed in both premalignant lesions and in malignant lung tumors, as well as in 40–80% of patien
Autor:
Vito Michele Garrisi, A. Paradiso, Ugo Pastorino, Elena Vaghi, Ines Abbate, Anita Mangia, Michele Quaranta, Domenico Galetta, Mattia Cremona, M. De Bortoli, Italia Bongarzone
Publikováno v:
Clinical biochemistry. 44(10-11)
Objectives The purpose of this study was to evaluate the efficacy of a protein-based pattern in serum previously determined by MALDI-TOF-MS (Matrix Assisted Laser Desorption Ionization-Time of Flight) and considered potentially useful for prediction
Autor:
Italia Bongarzone, Elena Vaghi, Elena Tamborini, Marco A. Pierotti, Francesca Miccichè, Fabio Bozzi, Silvana Pilotti, Veronica Huber, Luca Da Riva, Alessandro Gronchi, Eva Tarantino, Elena Fumagalli, Piera Mondellini
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 9, Iss 1, p 158 (2011)
Journal of Translational Medicine, Vol 9, Iss 1, p 158 (2011)
Background Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors to develop in the digestive tract. These tumors are highly resistant to conventional chemotherapy and only the introduction of imatinib mesylate has improved